Panelists discuss how data from Mansour and colleagues suggesting potential Bruton tyrosine kinase (BTK) inhibitor discontinuation after 2+ years of therapy opens up new treatment strategy ...

Following publication, concerns were raised regarding the integrity of the images in the published figures. Specifically, unexpected similarity was detected between western blot images presented in ...

Following publication, concerns were raised regarding the integrity of the images in the published figures. Specifically, unexpected similarity was detected between western blot images presented in ...

Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase first identified in a chromosomal translocation associated with some anaplastic large cell lymphomas (ALCL), a subset of T-cell non ...

The mechanistic target of rapamycin (mTOR) is a serine/threonine kinase whose activity contributes to leukemia proliferation and survival. Compounds targeting the mTOR active site inhibit ...

1Department of Thoracic/Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2The University of Texas MD Anderson Cancer Center, UTHealth Houston Graduate ...

including a Bruton tyrosine kinase (BTK) inhibitor. Cytokine Release Syndrome (CRS), including fatal or life-threatening reactions, occurred in patients receiving BREYANZI. Do not administer BREYANZI ...

Department of Pediatrics, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong 510080, China Department of Gastrointestinal Surgery, The First Affiliated Hospital, Sun Yat-sen ...

"If we want to stay healthy throughout our lives, we need to remember that keeping active is an important way of helping us achieve this goal. Those working at home might want to consider ...